| 1. |
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol, 1995, 13(1): 8-10.
|
| 2. |
Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study. Lancet Oncol, 2016, 17(12): 1672-1682.
|
| 3. |
Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol, 2018, 4(1): e173501.
|
| 4. |
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial. Lancet, 2019, 393(10185): 2051-2058.
|
| 5. |
Al-Batran SE, Homann N, Pauligk C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: The AIO-FLOT3 trial. JAMA Oncol, 2017, 3(9): 1237-1244.
|
| 6. |
Chen Y, Cheng X, Song H, et al, written on behalf of AME Radiation Oncology Collaborative Group. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. J Thorac Dis, 2019, 11(4): 1536-1545.
|
| 7. |
Kroese TE, Buijs GS, Burger MDL, et al. Metastasectomy or stereotactic body radiation therapy with or without systemic therapy for oligometastatic esophagogastric cancer. Ann Surg Oncol, 2022, 29(8): 4848-4857.
|
| 8. |
Kroese TE, van Laarhoven HWM, Schoppman SF, et al. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. Eur J Cancer, 2023, s185: 28-39.
|
| 9. |
Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol, 2014, 67(4): 401-409.
|
| 10. |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1. 1). Eur J Cancer, 2009, 45(2): 228-247.
|
| 11. |
Elliott JA, Markar SR, Klevebro F, et al. An international multicenter study exploring whether surveillance after esophageal cancer surgery impacts oncological and quality of life outcomes (ENSURE). Ann Surg, 2022, 277(5): e1035-e1044.
|
| 12. |
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet, 2021, 398(10294): s27-s40.
|
| 13. |
Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet, 2021, 398(10302): 759-771.
|
| 14. |
Ter Veer E, Haj Mohammad N, van Valkenhoef G, et al. The efficacy and safety of first-line chemotherapy in advanced esophagogastric cancer: A network meta-analysis. J Natl Cancer Inst, 2016, 108(10): .
|
| 15. |
Dijksterhuis WPM, Verhoeven RHA, Slingerland M, et al. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study. Int J Cancer, 2020, 146(7): 1889-1901.
|
| 16. |
Wagner AD, Grothe W, Behl S, et al.Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev, 2005, (2): CD004064.
|
| 17. |
Al-Batran SE, Goetze TO, Mueller DW, et al. The RENAISSANCE (AIO-FLOT5) trial: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction—A phase Ⅲ trial of the German AIO/CAO-V/CAOGI. BMC Cancer, 2017, 17(1): 893.
|
| 18. |
Ohkura Y, Shindoh J, Ueno M, et al. Clinicopathologic characteristics of oligometastases from esophageal cancer and long-term outcomes of resection. Ann Surg Oncol, 2020, 27(3): 651-659.
|
